The Isomorphic Labs Series C brings in $5 billion in new funding, the Alphabet-backed AI drug discovery company announced on Tuesday, November 17. The oversubscribed round was co-led by Greenoaks and Sequoia Capital, alongside Andreessen Horowitz and several other new investors, with continued significant investment from Alphabet. All of the company’s existing investors took part, including Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund, according to the company’s announcement.
The round closes a story that has been building for two weeks. Bloomberg reported on November 4 that Isomorphic was in talks to raise about $5 billion at a valuation of about $50 billion, a report GPTOnline covered at the time. The announcement itself does not disclose a valuation, and the final terms beyond the $5 billion figure and the investor list were not made public.
The scale is still striking. The new round is more than twice the $2.1 billion Series B the company closed in May 2026, which was led by Thrive Capital, and about eight times the $600 million first external round it raised in March 2025. In total, Isomorphic has now raised at least $7.7 billion in disclosed external funding in under two years, before counting Alphabet’s earlier backing.

What the Money Is For
Isomorphic says the capital will go into scaling its proprietary drug design engine, IsoDDE, and the therapeutic candidate pipeline built on it. IsoDDE unifies a suite of foundational simulation AI models that work across multiple therapeutic areas and drug modalities, exploring vast chemical spaces to design molecules with specific drug-like properties. The company says the breadth and precision of those models are pushing predictions toward experimental accuracy, and that the work is producing positive preclinical results for internal programs in oncology and immunology and for partnered programs.
The funding will also build the infrastructure around the science. The company plans to mature IsoDDE further, expand deeper into new areas of biology with more advanced models, build a partner ecosystem to advance understanding of disease biology, and construct the global infrastructure for what it calls AI-led bioengineering. That includes scalable AI-first translational and clinical development infrastructure as its drug candidates move toward clinical trials.
“When we founded Isomorphic, our conviction was that biology could be understood and modelled at the most fundamental molecular level and radically accelerated through AI,” said Sir Demis Hassabis, founder and CEO of Isomorphic Labs. “Our drug design engine is generating molecules with unprecedented precision and speed. This round enables us to accelerate our progress: building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programs towards clinical trials to deliver tangible impact for patients.”
The Road So Far
Isomorphic Labs was founded in 2021 as a spinout of Google DeepMind, built on the AlphaFold protein structure prediction work that won Hassabis a share of the 2024 Nobel Prize in Chemistry. The company is headquartered in London, with offices in Cambridge, Massachusetts and Lausanne, Switzerland, and is led by Hassabis as CEO and Max Jaderberg as president.
Its partnered pipeline includes programs with Novartis, Lilly and Johnson & Johnson, according to the company’s May 2026 announcement. The new investors joining the round, led by Sequoia and Greenoaks, are a sign of how far the company’s ambitions have moved from pure research toward becoming a drug developer in its own right.
“Every week we are making repeatable scientific advancements enabled by our models,” said Max Jaderberg, president of Isomorphic Labs. “These translate directly into better molecular profiles with the potential to be new medicines and unlock some of the hardest problems in drug discovery.”

Why It Matters
No Isomorphic-designed drug has yet been tested in people. The company’s programs remain preclinical, and the announcement describes them as “setting the stage for clinical entry” rather than entering trials. Hassabis has said he expected the first clinical trials to begin by the end of 2026, an expectation rather than a completed milestone, so the coming months will show whether the pipeline can make that jump.
That is what makes the $5 billion figure so notable. It is one of the largest private financings ever raised by an AI company, and it is being spent on a bet that has not yet produced a single human data point: that AI models can design medicines precisely enough to shorten the longest, most expensive part of drug development. If the first trials start on schedule and the molecules behave as the models predict, Isomorphic will have a credible claim to a new way of making drugs. If they do not, the round will stand as the high-water mark of investor confidence in AI drug discovery.
For now, the market’s answer is unambiguous. An oversubscribed $5 billion round, co-led by two of Silicon Valley’s most prominent firms and joined by every existing backer, is a vote that the science is ready to be tested in the clinic. The test itself is still to come.
Sources
- Isomorphic Labs (PR Newswire): Isomorphic Labs announces $5 Billion Series C funding
- Bloomberg Tax: Sequoia, Greenoaks Lead Isomorphic Lab $5 Billion Funding Round
- Techmeme: Alphabet’s Isomorphic Labs raised a $5B Series C
- FourWeekMBA: Alphabet’s Isomorphic in Talks for $5B at $50B
- GPTOnline: Isomorphic Labs in Talks to Raise $5B at $50B Valuation


[…] on GPTOnline: Isomorphic Labs Raises $5 Billion in Series C Funding and Corma 1 Billion Valuation With $125M AI Security […]